Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients.

NCT04729595 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

248

Enrollment

INDUSTRY

Sponsor class

Stopped Study did not demonstrate statistical significance of its primary endpoint of clinical resolution of COVID-19 symptoms at day 14 versus placebo

Conditions

Covid19

Interventions

DRUG: Tempol
OTHER: Placebo

Sponsor

Adamis Pharmaceuticals Corporation